参考文献/References:
[1].Ference BA,Ginsberg HN,Graham I,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic,epidemiologic,and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2017,38(32):2459-2472.
[2].Malakar AK,Choudhury D,Halder B,et al. A review on coronary artery disease,its risk factors,and therapeutics[J]. J Cell Physiol,2019,234(10):16812-16823.
[3].Ridker PM,MacFadyen JG,Thuren T,et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab:further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis[J]. Eur Heart J,2020,41(23):2153-2163.
[4].Libby P. Inflammation in atherosclerosis—No longer a theory[J]. Clin Chem,2021,67(1):131-142.
[5].Ruparelia N,Choudhury R. Inflammation and atherosclerosis:what is on the horizon[J]? Heart,2020,106(1):80-85.
[6].Boland J,Long C. Update on the inflammatory hypothesis of coronary artery disease[J]. Curr Cardiol Rep,2021,23(2):6.
[7].Ridker PM,Morrow DA,Rose LM,et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol＜70 mg/dl and C-reactive protein＜2 mg/l:an analysis of the PROVE-IT TIMI-22 trial[J]. J Am Coll Cardiol,2005,45(10):1644-1648.
[8].Ridker PM,Danielson E,Fonseca FA,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med,2008,359(21):2195-2207.
[9]. Ridker PM,Bhatt DL,Pradhan AD,et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy:a collaborative analysis of three randomised trials[J]. Lancet,2023,401(10384):1293-1301.
[10]. Paramel Varghese G,Folkersen L,Strawbridge RJ,et al. NLRP3 inflammasome expression and activation in human atherosclerosis [J]. J Am Heart Assoc,2016,5(5):e003031.
[11]. Silvis MJM,Demkes EJ,Fiolet ATL,et al. Immunomodulation of the NLRP3 inflammasome in atherosclerosis,coronary artery disease,and acute myocardial infarction[J]. J Cardiovasc Transl Res,2021,14(1):23-34.
[12]. Libby P. Interleukin-1 Beta as a target for atherosclerosis?therapy:biological basis of CANTOS?and?beyond[J]. J Am Coll Cardiol,2017,70(18):2278-2289.
[13]. Eghtedari B ,Roy SK,Budoff MJ. Anti-inflammatory therapeutics and coronary artery disease[J]. Cardiol Rev,2023,31(2):80-86.
[14]. Kaplanski G. Interleukin-18:biological properties and role in disease pathogenesis[J]. Immunol Rev,2018,281(1):138- 153.
[15].Libby P,Tabas I,Fredman G,et al. Inflammation and its resolution as determinants of acute coronary syndromes[J]. Circ Res,2014,114(12):1867-1879.
[16]. Interleukin-6 Receptor Mendelian Randomisation Analysis(IL6R MR) Consortium ,Swerdlow DI,Holmes MV,et al. The interleukin-6 receptor as a target for prevention of coronary heart disease:a mendelian randomisation analysis[J]. Lancet,2012,379(9822):1214-1224.
[17].Blankenberg S,Tiret L,Bickel C,et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina[J]. Circulation,2002,106(1):24-30.
[18].Zheng F,Xing S,Gong Z,et al. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis[J]. Heart Lung Circ ,2013,22(9):746-750.
[19].Satoh M,Tabuchi T,Itoh T,et al. NLRP3 inflammasome activation in coronary artery disease:results from prospective and randomized study of treatment with atorvastatin or rosuvastatin[J]. Clin Sci(Lond),2014,126(3):233-241.
[20]. Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[21]. McInnes IB,Thompson L,Giles JT,et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis:MEASURE,a randomised,placebo-controlled study [J]. Ann Rheum Dis,2015,74(4):694-702.
[22]. Ridker PM,Devalaraja M,Baeres FMM,et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk(RESCUE):a double-blind,randomised,placebo-controlled,phase 2 trial[J]. Lancet,2021,397(10289):2060-2069.
[23].王大震,俞梦越. 冠心病抗炎治疗通路现状与展望[J]. 心血管病学进展,2022,43(7):586-589,599.
[24]. Tardif JC,L’allier PL,Ibrahim R,et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome[J]. Circ Cardiovasc Imaging,2010,3(3):298-307.
[25]. Almeida SO,Ram RJ,Kinninger A,et al. Effect of 5-lipoxygenase inhibitor,VIA-2291(Atreleuton),on epicardial fat volume in patients with recent acute coronary syndrome[J]. J Cardiovasc Comput Tomogr,2020,14(4):343-348.
[26]. Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med ,2019,381(26):2497-2505.
[27]. Bouabdallaoui N,Tardif JC,Waters DD,et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial(COLCOT)[J]. Eur Heart J ,2020,41(42):4092-4099.
[28]. Nidorf SM,Eikelboom JW,Budgeon CA,et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol,2013 ,61(4):404-410.
[29]. Nidorf SM,Fiolet ATL,Eikelboom JW,et al. The effect of low-dose colchicine in patients with stable coronary artery disease:the LoDoCo2 trial rationale,design,and baseline characteristics[J]. Am Heart J,2019,218:46-56.
[30]. D’Amario D,Cappetta D,Cappannoli L,et al. Colchicine in ischemic heart disease:the good,the bad and the ugly[J]. Clin Res Cardiol,2021,110(10):1531-1542.
[31]. Micha R,Imamura F,Wyler von Ballmoos M,et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease[J]. Am J Cardiol,2011,108(9):1362- 1370.
[32]. Ridker PM,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[33].Beckers CML,Simpson KR,Griffin KJ,et al. Cre/lox Studies identify resident macrophages as the major source of circulating coagulation factor XIII-A [J]. Arterioscler Thromb Vasc Biol,2017,37(8):1494-1502.
[34].Smith HW,Marshall CJ. Regulation of cell signalling by uPAR[J]. Nat Rev Mol Cell Biol,2010,11(1):23-36.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(3):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(3):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(3):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(3):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(3):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[11]王大震 俞梦越.冠心病抗炎治疗通路现状与展望[J].心血管病学进展,2022,(7):586589.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Dazhen,YU Mengyue.Status and Prospect of Anti-inflammatory Therapeutic Pathway for Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2022,(3):586589.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]